Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
3.070
+0.170 (5.86%)
At close: Oct 11, 2024, 4:00 PM
3.220
+0.150 (4.89%)
After-hours: Oct 11, 2024, 6:20 PM EDT
Organogenesis Holdings Employees
Organogenesis Holdings had 862 employees as of December 31, 2023. The number of employees decreased by 168 or -16.31% compared to the previous year.
Employees
862
Change (1Y)
-168
Growth (1Y)
-16.31%
Revenue / Employee
$520,176
Profits / Employee
-$19,194
Market Cap
407.01M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cross Country Healthcare | 13,131 |
| Ginkgo Bioworks Holdings | 1,218 |
| Sage Therapeutics | 487 |
| Talkspace | 472 |
| Verve Therapeutics | 255 |
| Jin Medical International | 245 |
| MaxCyte | 143 |
| Theravance Biopharma | 99 |
ORGO News
- 10 days ago - Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers - GlobeNewsWire
- 5 weeks ago - Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September - GlobeNewsWire
- 2 months ago - Organogenesis Holdings, Inc. (ORGO) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Organogenesis Shares ReNu® Program Update - GlobeNewsWire
- 3 months ago - Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024 - GlobeNewsWire
- 4 months ago - Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference - GlobeNewsWire
- 5 months ago - Organogenesis Holdings, Inc. (ORGO) Q1 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis - GlobeNewsWire